Some selected patients may benefit from the dual-tracer approach, but more and larger prospective studies are needed to assess the role of PSMA PET/CT in the disease monitoring of these patients and to better explore the performance of the 177Lu-PSMA RLT in selected thyroid cancers. The gene discussed is FOLH1; the disease is thyroid gland carcinoma.